Time Trends in the Burden of Hospitalizations with Invasive Aspergillosis in the United States, 2004–2013. (4th October 2017)

• Record Type: Journal Article
• Authors: Zilberberg, Marya D; Harrington, Rachel; Spalding, James; Shorr, Andrew F
• Is Part Of: Open forum infectious diseases. Volume 4(2017)Supplement 1
• Page Start: S73
• Page End: S74
• Publication Date: 2017-10-04
• Subjects: Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofx163.006
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: Invasive aspergillosis (IA) remains a burdensome illness and is associated with substantial mortality. With increasing use of aggressive chemotherapy and immunomodulatory treatments, the prevalence of IA is likely to have grown. However, little is known about the current US burden of IA-related hospitalizations. Methods: Using aggregated data available on the interactive website from the Agency of Healthcare Research and Quality's Health Care Utilization Project Net, we examined the annual volume of IA-related hospitalizations in the United States, based on the presence of the ICD-9-CM codes 117.3, 117.9, and 484.6. Age-adjusted volumes were derived through population incidence calculated using year-specific censal and intercensal US population estimates available from the US Census Bureau. We additionally determined time trends in IA as the principal diagnosis (PD) and its associated charges. Results: Between 2004 and 2013, the number of annual hospitalizations with IA grew from 29, 774 (standard error, SE 2, 425) to 51, 870 (SE 2, 642), a 74.2% overall increase. This increase was most notable among those aged 45–64 and 65–84 years. Regionally, the South contributed the plurality of the cases (40%), and the Northeast the fewest (17%) with the remainder split evenly between the West and the Midwest. When age-adjusting to year 2013, the growth in the volume of cases was slightly more modest (44.2%), going from 35, 968 cases in 2004 to 51, 870 in 2013. The proportion of IA hospitalizations in which IA was the PD dropped, from 14.4% in 2004 to 9.3% in 2013. Despite mean hospital length of stay (LOS) decreasing from 13.3 (SE 0.07) in 2004 to 11.5 (SE 0.6) days in 2013, the corresponding mean hospital charges rose from $71, 164 (SE $5, 248) to $123, 005 (SE $9, 738). The aggregate US inflation-adjusted hospital charges for IA PD rose from $436, 074, 445 in 2004 to $592, 358, 369 in 2013. Conclusion: The rate of growth in IA-related hospitalizations in the United States between 2004 and 2013 was substantial. The plurality of cases appears to arise in the South. Despite a moderate decrease in LOS during the time period studied, there was a modest rise in the corresponding hospital charges. The aggregate US annual hospital bill for IA PD discharges is over $0.5 billion. Disclosures: M. D. Zilberberg, Astellas Pharma Global Development, Inc.: grant investigator, research support R. Harrington, Astellas Pharma Global Development, Inc.: employee, former employee and salary J. Spalding, Astellas Pharma Global Development, Inc.: employee, salary A. F. Shorr, Astellas Pharma Global Development, Inc.: Consultant and Speaker's Bureau, consulting fee, research support and speaker honorarium Cidara: consultant, consulting fee Merck: consultant, scientific advisor and Speaker's Bureau, research support and speaker honorarium